This application is a proposal to serve as the Statistical and Data Management Center of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT), in affiliation with the IMPAACT Leadership Group headed by Dr. J. Brooks Jackson (JHU). IMPAACT is proposing a therapeutic research agenda to address objectives in the NIAID high priority research areas of Prevention of Mother-to-Child Transmission of HIV Infection;Translational Research/Drug Development;Optimization of Clinical Management;and Vaccine Research and Development.
The Specific Aims are to support the research agenda of IMPAACT by providing a group of highly experienced statisticians, data managers and other professionals who are knowledgeable in all aspects of HIV therapeutic research and an organizational structure that promotes this work with IMPAACT;to provide expertise and high quality clinical and laboratory data management and communications systems to support the development, conduct, and analysis of IMPAACT studies;and to advance the mission of IMPAACT through innovation in study design and analysis, providing leadership in cross-study analyses and collaborating effectively with other HIV Trials Networks and HIV research organizations.
|Gupta, Amita; Mathad, Jyoti S; Abdel-Rahman, Susan M et al. (2016) Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. Clin Infect Dis 62:761-9|
|Hughes, Paul; Deng, Wenjie; Olson, Scott C et al. (2016) Short Communication: Analysis of Minor Populations of Human Immunodeficiency Virus by Primer Identification and Insertion-Deletion and Carry Forward Correction Pipelines. AIDS Res Hum Retroviruses 32:296-302|
|Brummel, Sean S; Singh, Kumud K; Maihofer, Adam X et al. (2016) Associations of Genetically Determined Continental Ancestry With CD4+ Count and Plasma HIV-1 RNA Beyond Self-Reported Race and Ethnicity. J Acquir Immune Defic Syndr 71:544-50|
|Beneri, C A; Aaron, L; Kim, S et al. (2016) Understanding NIH clinical case definitions for pediatric intrathoracic TB by applying them to a clinical trial. Int J Tuberc Lung Dis 20:93-100|
|Fowler, Mary G; Qin, Min; Fiscus, Susan A et al. (2016) Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med 375:1726-1737|
|Kapogiannis, Bill G; Leister, Erin; Siberry, George K et al. (2016) Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth. AIDS 30:889-98|
|Barlow-Mosha, Linda; Angelidou, Konstantia; Lindsey, Jane et al. (2016) Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Clin Infect Dis 63:1113-21|
|Wolf, Elizabeth; Herbeck, Joshua T; Van Rompaey, Stephen et al. (2016) Phylogenetic Evidence of HIV-1 Transmission Between Adult and Adolescent Men Who Have Sex with Men. AIDS Res Hum Retroviruses :|
|Price, Joan T; Wheeler, Stephanie B; Stranix-Chibanda, Lynda et al. (2016) Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. J Acquir Immune Defic Syndr 72 Suppl 2:S145-53|
|Foca, Marc; Yogev, Ram; Wiznia, Andrew et al. (2016) Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults. Pediatr Infect Dis J 35:e271-4|
Showing the most recent 10 out of 93 publications